免疫检查点抑制剂联合抗血管生成治疗改善非小细胞肺癌的免疫耐药

郭 万晶1, 姜 军*2
1、青海大学
2、青海大学附属医院肿瘤内科三病区

摘要


免疫治疗显著改变了非小细胞肺癌（non-small cell lung cancer，NSCLC）的治疗格局，但由于免疫耐药的存在，使患者无法持久获益。基于血管生成在免疫耐药及免疫调节中的作用，将免疫检查点抑制剂与抗血管生成治疗相结合，是改善NSCLC免疫耐药的重要研究方向。此文主要对与血管生成有关的NSCLC免疫耐药机制、联合治疗作用及其相关临床研究进行了综述。

关键词


免疫治疗；免疫检查点抑制剂；血管生成；抗血管生成治疗；免疫耐药；非小细胞肺癌

全文:

PDF


参考


[1]景亚婉，曾灏，程睿欣，田攀文，李亚伦.非小细胞肺癌免疫耐药机制及应对策略的研究进展[J].中国肺癌杂志，2023，26（1）：66-77

[2]Kim CG, Jang M, Kim Y, Leem G, Kim KH, Lee H, et al. VEGF-A drives TOX-dependent T cell exhaustion in anti-PD-1-resistant microsatellite stable colorectal cancers. Sci Immunol. 2019;4:eaay0555.

[3]Huinen,Zowi R.,et al. "Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes". Nature Reviews Clinical Oncology,vol.18,2021,pp.527-540.

[4]Klein, D. The tumor vascular endothelium as decision maker in cancer therapy. Front. Oncol. 8, 367 (2018). 58. Kuzu, I. et al. Heterogeneity of vascular endothelial cells with relevance to diagnosis of vascular tumours.

[5]Krausgruber, T. et al. Structural cells are key regulators of organ-specific immune responses. Nature

[6]Jambusaria, A. et al. Endothelial heterogeneity across distinct vascular beds during homeostasis and inflammation. eLife 9, e51413 (2020).

[7]Amersfoort,Jacob,et al. "Immunomodulation by endothelial cells — partnering up with the immune system?".Frontiers in Immunology,vol.22,2022,pp.576-588.

[8]Goveia, J. et al. An integrated gene expression landscape profiling approach to identify lung tumor endothelial cell heterogeneity and angiogenic candidates. Cancer Cell 37, 21-36.e13 (2020).

[9]Kreisel, D. et al. Cutting edge: MHC class II expression by pulmonary nonhematopoietic cells plays a critical role in controlling local inflammatory responses. J. Immunol. 185, 3809-3813 (2010).

[10]Kim, N. et al. Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma. Nat. Commun. 11, 2285 (2020).

[11]Yi M, Jiao D, Qin S, Chu Q, Wu K, Li A. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer. 2019;18(1):60. Published 2019 Mar 30.

[12]Kim DJ, Anandh S, Null JL, et al. Priming a vascular-selective cytokine response permits CD8+ T-cell entry into tumors. Nat Commun. 2023;14(1):2122. Published 2023 Apr 14.

[13]Missiaen R, Mazzone M, Bergers G. The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer. Semin Cancer Biol. 2018;52(Pt 2):107-116.

[14]Asrir A, Tardiveau C, Coudert J, et al. Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy. Cancer Cell. 2022;40(3):318-334.e9.

[15]Hua Y, Vella G, Rambow F, et al. Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1 T lymphocyte niches through a feed-forward loop [published correction appears in Cancer Cell. 2023 Jan 9;41(1):226]. Cancer Cell. 2022;40(12):1600-1618.e10.

[16]柳菁菁，张良，张爽，程颖.肺癌免疫治疗的研究进展[J].中国肿瘤临床，2023，50（1）：1-7

[17]Lee J, Koh J, Kim HK, et al. Bevacizumab Plus Atezolizumab After Progression on Atezolizumab Monotherapy in Pretreated Patients With NSCLC: An Open-Label, Two-Stage, Phase 2 Trial. J Thorac Oncol. 2022;17(7):900-908.

[18]Reckamp KL, Redman MW, Dragnev KH, et al. Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A [published correction appears in J Clin Oncol. 2022 Sep 1;40(25):3002]. J Clin Oncol. 2022;40(21):2295-2306.

[19]S. Puri, T. Tanvetyanon, B. Creelan, et al, MA13.02 Phase II study of nivolumab and ipilimumab combined with nintedanib in recurrent non-small cell lung cancer, J. Thorac. Oncol. 16 (Suppl10) (2021) S924-S925.

[20]Grohé C, Wehler T, Dechow T, et al. Nintedanib plus docetaxel after progression on first-line immunochemotherapy in patients with lung adenocarcinoma: Cohort C of the non-interventional study, VARGADO. Transl Lung Cancer Res. 2022;11(10):2010-2021.

[21]S. Puri, T. Tanvetyanon, B. Creelan, et al, MA13.02 Phase II study of nivolumab and ipilimumab combined with nintedanib in recurrent non-small cell lung cancer, J. Thorac. Oncol. 16 (Suppl10) (2021) S924-S925.

[22]He K, Berz D, Gadgeel SM, et al. MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy. J Thorac Oncol. 2023;18(7):907-921.

[23]Neal, Joel W. et al. "Cabozantinib (C) plus atezolizumab (A) or C alone in patients (pts) with advanced non-small cell lung cancer (aNSCLC) previously treated with an immune checkpoint inhibitor (ICIs): Results from Cohorts 7 and 20 of the COSMIC-021 study." Journal of Clinical Oncology (2022): n. pag.


Refbacks

  • 当前没有refback。